Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Liabilities (2018 - 2025)

Bicycle Therapeutics' Total Liabilities history spans 8 years, with the latest figure at $107.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 34.3% year-over-year to $107.6 million; the TTM value through Dec 2025 reached $107.6 million, down 34.3%, while the annual FY2025 figure was $107.6 million, 34.3% down from the prior year.
  • Total Liabilities reached $107.6 million in Q4 2025 per BCYC's latest filing, down from $145.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $234.1 million in Q2 2023 to a low of $81.8 million in Q1 2021.
  • Average Total Liabilities over 5 years is $153.6 million, with a median of $144.5 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: surged 103.28% in 2021, then tumbled 34.3% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $133.5 million in 2021, then rose by 4.71% to $139.8 million in 2022, then soared by 60.49% to $224.4 million in 2023, then fell by 27.01% to $163.8 million in 2024, then crashed by 34.3% to $107.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Total Liabilities are $107.6 million (Q4 2025), $145.5 million (Q3 2025), and $163.3 million (Q2 2025).